Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific director share transactions and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document focuses solely on the personal share transactions of Sir Andrew Witty, a Director.
Management Commentary and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies in this filing. The content is strictly a regulatory disclosure of a director's share option exercise and subsequent sale.
Important Facts for Investors
- Director Transaction: Sir Andrew Witty exercised options over 77,500 Ordinary Shares on October 23, 2014.
- Option Details: The options were granted on December 2, 2004, under the GlaxoSmithKline Share Option Plan at an exercise price of £11.23 per share.
- Share Sale: On the same date, 71,296 Ordinary Shares were sold at a price of £13.84 per share.
- Reporting Date: The Company was advised of the transaction on October 23, 2014.